Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients (OH)

This study has been terminated.
Information provided by (Responsible Party):
TSH Biopharm Corporation Limited Identifier:
First received: June 1, 2012
Last updated: March 11, 2013
Last verified: March 2013
Orthostatic hypotension is a major complication of hemodialysis and interferes with everyday activities in hemodialysis patients. Since information regarding the use of droxidopa in clinical trials relating to orthostatic hypotension of chronic hemodialysis patients is limited in Taiwan, this study is designed for evaluation the efficacy and safety profile of droxidopa on orthostatic hypotension treatment / prevention in hemodialysis patients.

Condition Intervention Phase
Orthostatic Hypotension
Drug: Droxidopa
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized and Placebo-controlled Study to Evaluate the Efficacy and Safety of L-threo-3,4-dihydroxyphenylserine (Droxidopa) on Orthostatic Hypotension Treatment in Hemodialysis Patients

Resource links provided by NLM:

Further study details as provided by TSH Biopharm Corporation Limited:

Primary Outcome Measures:
  • Change in mean ΔSBP after hemodialysis [ Time Frame: from Week 0 (visit 1-3) to Week 4 (visit 13-15) ]
    ΔSBP = supine SBP (right before standing up) - nadir standing SBP

Secondary Outcome Measures:
  • Adverse event,Serious adverse event [ Time Frame: from week 0 to week 5 ]

Enrollment: 25
Study Start Date: June 2012
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Droxidopa, antihypotensive drug, tablet Drug: Droxidopa
200mg/tab 2tablets, po, three times a week
Placebo Comparator: placebo, tablet Drug: Placebo
200mg/tab, po, three times a week.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Female or male aged great than 20 years of age
  2. Patient with at least 3 month documented requirement of regular hemodialysis session
  3. Patient with a decrease of 20 mmHg in SBP or 10 mmHg in DBP within 5 minutes of standing after the end of hemodialysis in at least 2 of 3 sessions during the screening period.
  4. Subject with subjective complain of light headedness related to the orthostatic hypotension AND with a VAS score 4 in at least 2 of 3 sessions during the screening period.
  5. Willing and able to comply with the study procedure and sign a written informed consent

Exclusion Criteria:

  1. Female who is pregnant, lactating or planning to be pregnant within 3 months, or female of childbearing potential who is not using medically recognized method of contraception
  2. Subject with closed angle glaucoma
  3. Subject with severe hypertension
  4. Subject with liver disorder
  5. Subject with Hct great than 36%
  6. Subject with confusion, hallucination, or delusion
  7. Subject with severe disease which may limit survival during the study period, or confound the results of the study as judged by the investigator, such as hyperthyroidism, artery stenosis, severe lung disorders, severe asthma, chronic open angle glaucoma, uncontrolled diabetic gangrene
  8. Subject who takes any anti-hypotensive drugs within 7 days prior to randomization, such as midodrine, etilefrine or amezinium
  9. Subject who takes ephedrine, pseudoephedrine within 7 days prior to randomization
  10. Subject who use of any investigational product within 4 weeks prior to randomization
  11. Subject who requires blood transfusions within 3 months before screening, and are not suitable to participate the trial as judged by the investigator
  12. Histories of hypersensitive to droxidopa
  13. Histories of peripheral vascular disease, coronary artery disease and are not suitable to participate the trial as judged by the investigator
  14. Histories of hemorrhage complication within 3 months before the screening visit, such as GI bleeding, intracranial bleeding or traumatic hemorrhage, and are not suitable to participate the trial as judged by the investigator
  15. In investigator's opinion, subjects who are unlikely to adequately cooperate and follow the procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01612078

Taipei Medical University Hospital
Taipei, Taiwan
Sponsors and Collaborators
TSH Biopharm Corporation Limited
Principal Investigator: Mai-Szu Wu Taipei Medical University Hospital
  More Information

Responsible Party: TSH Biopharm Corporation Limited Identifier: NCT01612078     History of Changes
Other Study ID Numbers: TSHDX1101
Study First Received: June 1, 2012
Last Updated: March 11, 2013

Additional relevant MeSH terms:
Hypotension, Orthostatic
Orthostatic Intolerance
Vascular Diseases
Cardiovascular Diseases
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents processed this record on May 25, 2017